Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Hogan

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Blood Advances|April 27, 2021
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patientsMarissa Li, Moritz Binder, Terra Lasho, et al.
Transplantation and Cellular Therapy|April 7, 2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012Claudio G Brunstein, Paul V O'Donnell, Brent Logan, et al.
Haematologica|January 8, 2026
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromesMahmood Aldapt, Yu-Hung Wang, Kashish J Shah, et al.
Journal of the American Medical Informatics Association : JAMIA|October 6, 2021
Extracting social determinants of health from electronic health records using natural language processing: a systematic reviewBraja G Patra, Mohit M Sharma, Veer Vekaria, et al.
American Journal of Clinical Pathology|August 8, 2022
Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined SignificanceDragan Jevremovic, Ahmad Nanaa, Susan M Geyer, et al.
Blood Advances|October 25, 2024
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysisJoseph Pidala, Jongphil Kim, Denise Kalos, et al.
Diabetes, Obesity & Metabolism|September 30, 2024
Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research networkPiaopiao Li, Eliot Spector, Khalid Alkhuzam, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Applied Clinical Informatics|April 6, 2017
The Building Blocks of Interoperability. A Multisite Analysis of Patient Demographic Attributes Available for MatchingAdam Culbertson, Satyender Goel, Margaret B Madden, et al.
American Journal of Hematology|December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survivalOmer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Blood Advances|April 27, 2021
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patientsMarissa Li, Moritz Binder, Terra Lasho, et al.
Transplantation and Cellular Therapy|April 7, 2022
Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012Claudio G Brunstein, Paul V O'Donnell, Brent Logan, et al.
Haematologica|January 8, 2026
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromesMahmood Aldapt, Yu-Hung Wang, Kashish J Shah, et al.
Journal of the American Medical Informatics Association : JAMIA|October 6, 2021
Extracting social determinants of health from electronic health records using natural language processing: a systematic reviewBraja G Patra, Mohit M Sharma, Veer Vekaria, et al.
American Journal of Clinical Pathology|August 8, 2022
Abnormal CD13/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined SignificanceDragan Jevremovic, Ahmad Nanaa, Susan M Geyer, et al.
Blood Advances|October 25, 2024
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysisJoseph Pidala, Jongphil Kim, Denise Kalos, et al.
Diabetes, Obesity & Metabolism|September 30, 2024
Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research networkPiaopiao Li, Eliot Spector, Khalid Alkhuzam, et al.
Haematologica|July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Applied Clinical Informatics|April 6, 2017
The Building Blocks of Interoperability. A Multisite Analysis of Patient Demographic Attributes Available for MatchingAdam Culbertson, Satyender Goel, Margaret B Madden, et al.
American Journal of Hematology|December 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survivalOmer Karrar, Maymona Abdelmagid, Masooma Rana, et al.
Pageof 11